November 9, 2021 5:00pm
Sector earnings season is half way over, so I don’t see a reason to add exposure just quite yet
Pre-open indication results: 5 HITs, 3 MISS
The Biostage (BSTG) Chronicles: closed -$0.03 even after being “pumped/promoted” with 3,304 shares traded following Monday’s +$0.07 with 7,0882 shares traded after Friday’s flat $0.00 at $2.60 with 9,003 shares traded
If you’re looking for sector intel, ideas and facts or Insight in a volatile climate, RMi defines the extenuating factors of share pricing. Who else is tracking a broad representative index of cell and gene therapy equities – the facts are supported by real numbers?
The Dow closed DOWN -112.24 points (-0.31%); the S&P closed DOWN -16.45 points (-0.35%) while the Nasdaq closed DOWN -95.81 points (-0.60%)
Henry’omics:
Indexes slid on Tuesday, bringing a multi-day rally of straight record closing highs to a close as profit-taking and worries over ongoing inflation fueled a broad sell-off.
Economic Data Docket: The Labor Department's producer prices (PPI) report showed inflation continues to gather heat as ongoing goods and labor supply challenges send price growth further beyond the Fed's average annual 2% inflation target.
Note: Biostage (BSTG) dumped -$0.03 with 3,304 shares traded after Monday’s +$0.07 after being up +$0.60 with 7,082 shares traded, Friday’s flat $0.00 with 9,003 shares traded, Thursday’s flat at $2.60 with 82 shares traded, Wednesday’s down -$0.40 to $2.60 with 1,208 shares traded, Tuesday’s -$0.10 to $3.00 with 200 shares traded, flat again $0.00 on Monday with 80 shares traded to $3.10 after last Friday’s 162 shares traded, Thursday’s 95 shares traded and previous Wednesday’s move from -$0.40 with 216 shares traded until the “pump” was turned-on with 1,676 shares traded to close +$0.10 – where is the SEC?
RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what’s happening …
- Tuesday opened negative at 13/20, 1 flat and 1 acquired, stayed negative at the mid-day at 8/24, 2 flats and 1 acquired, ending with a negative close of 9/24, 1 flat and 1 acquired;
- Monday opened negative at 12/19, 3 flats and 1 acquired, stayed negative at the mid-day at 15/18, 3 flats, 1 flat and 1 acquired, ending with a negative close of 16/17, 2 flats and 1 acquired;
RegMed Investors’ (RMi) pre-open: “RegMed Investors’ (RMi) pre-open: a sector retreat is not a defeat; it will just move directionally. Still watching the earnings releases.” … https://www.regmedinvestors.com/articles/12175
Pre-open indication results: 5 HITs: < Biostage (BSTG -$0.03), Ionis Pharmaceuticals (IONS -$0.88), ReNeuron (RENE.L $0.00), Intellia Therapeutics (NTLA +$2.29), Fate Therapeutics (FATE +$0.23)> and 3 MISS <Chinook Therapeutics (KDNY +$0.32), BioLife Solutions (BLFS +$0.28), Editas Medicine (EDIT -$0.01)>
Earnings results:
Applied Genetic Technologies (AGTC) had a Q4 net loss of -$17.1 m, a negative loss per share of -$0.40, a cash position of $90.6 m with NO revenue but, a doubling of interest (from Hercules ATM) from Q3/20,
Vericel (VCEL) had a Q3 net loss of -$4.9 m, a negative loss per share of -$0.11, a cash position of $119 m, revenues increased by $2 m ($34.5 m versus $32.5 m) versus Q3/20,
Key Metric - volume:
Sector volume LOW with 4 of the 9-upside having higher than the 3-month average volume with LOW volume of 5 of 24-downside having higher than the 3-month average volume;
There are clear winners and losers
Jumping with share pricing momentum (9 of 9):
- Intellia Therapeutics (NTLA +$2.29 after Monday’s +$0.59),
- Chinook Therapeutics (KDNY +$0.32 after Monday’s -$1.77 and a proposed offering),
- BioLife Solutions (BLFS +$0.28 after Monday’s -$0.59),
- Pluristem (PSTI +$0.26 after Monday’s +$0.07),
- Fate Therapeutics (FATE +$0.23 after Monday’s +$1.77),
- bluebird bio (BLUE +$0.18 after Monday’s -$2.40),
- Solid Biosciences (SLDB +$0.05),
- Brainstorm Cell Therapeutics (BCLI +$0.04),
- Adverum Biotechnologies (ADVM +$0.03),
Hammered in today’s market (10 of 24):
- Alnylam Pharmaceuticals (ALNY -$4.05 after Monday’s +$0.72),
- CRISPR Therapeutics (CRSP -$2.87 after Monday’s +$3.90),
- Global Blood Therapeutics (GBT -$1.94),
- Ultragenyx (RARE -$1.68 after Monday’s -$0.74),
- Sage Therapeutics (SAGE -$1.05 after Monday’s -$0.73),
- uniQure NV (QURE -$0.96),
- Vericel (VCEL -$0.95 after Monday’s -$2.95),
- AxoGen (AXGN -$0.92 after Monday’s +$0.58),
- Ionis Pharmaceuticals (IONS -$0.88 after Monday’s +$1.19),
- Cellectis SA (CLLS -$0.46 after Monday’s -$0.56),
Closing Flat:
- 1 –ReNeuron (RENE.L) and 1 - Stemline Therapeutics (STML) – acquired
Stats:
The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:
- Tuesday, the IBB closed down -1.34% and XBI closed down -1.44%
The CBOE Volatility Index (VVIX: INDEX) tracked:
- Tuesday was up +0.56 points or +3.25% at 17.78
November, the second month of Q4/21:
Tuesday closed negative with 9 incliners, 24 decliners, 1 flat and 1 acquired
Monday (11/8) closed negative with 16 incliners, 17 decliners, 2 flats and 1 acquired
The BOTTOM LINE: the week fade as it trades again!
Expected Q3 earnings …
We are seeing to date,
- One (1) net income – Bellicum Pharmaceuticals (BLCM),
- Twenty-one (21) net losses to date <uniQure (QURE), Alnylam Pharmaceuticals (ALNY), Regenxbio (RGNX), Sage Therapeutics SAGE), Ultragenyx Pharmaceuticals (RARE), Voyager Therapeutics (VYGR), Solid Biosciences (SLDB), Ionis Pharmaceuticals (IONS), CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA), Caladrius Biosciences (CLBS), AxoGen (AXGN), Adverum Biotechnologies (ADVM), Verastem (VSTM), Global Blood Therapeutics (GBT), Fate Therapeutics (FATE), Sangamo Therapeutics (SGMO), Cellectis SA (CLLS), Editas Medicine (EDIT) and today’s … Applied Genetic Technologies (AGTC) and Vericel (VCEL)>
- Q3 earnings reporting season began the tug-of-war between share pricing that is softer than usual and the usual LPS (loss-per-share) to be less than estimates and expectations.
The stem, cell and gene therapy earnings remaining with Vericel (VCEL) and Applied Genetic Technologies (AGTC) on 11/9, BioLife Solutions BLFS) on 11/11 followed by Athersys (ATHX) and Brainstorm Cell Therapeutics (BCLI) coming 11/15 (to date).
Reiterating, “the stem, cell and gene therapy sector is still seen as vulnerable to extreme low volume moves in either direction, as share pricing risk stimulates their susceptibility!”
I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”
WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!
Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations? What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
